Drug General Information (ID: DDI1EASJ5N)
Drug Name			Conjugated estrogens (topical)		Drug Info		Warfarin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Estrogens				Anticoagulants
Structure

Mechanism of Conjugated estrogens (topical)-Warfarin Interaction (Severity Level: Moderate)
Antagonize the effect of antithrombotic agents Click to Show/Hide Mechanism Graph
Drug Name		Conjugated estrogens (topical)				Warfarin
Mechanism		Thrombogenic effects				Anticoagulant
Key Mechanism Factor 1
		Factor Name		Antithrombotic agents
		Factor Description		The beneficial effects of antithrombotic agents are reduced, leading to an increased risk of thromboembolism, stroke and/or myocardial infarction.
Mechanism Description		Antagonize the effect of Warfarin when combined with Conjugated estrogens (topical)

Recommended Action
Management		Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks. Close clinical and laboratory monitoring are recommended if the combination is prescribed. Patients should be advised to promptly notify their physician if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity.

References
1	Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83. [PMID: 3987135]
2	Stangel JJ, Innerfield I, Reyniak JV, Stone ML "The effect of conjugated estrogens on coagulability in menopausal women." Obstet Gynecol 49 (1977): 314-6. [PMID: 190571]
3	von Kaulla E, Droegemueller W, von Kaulla KN "Conjugated estrogens and hypercoagulability." Am J Obstet Gynecol 122 (1975): 688-92. [PMID: 15850603]